Proficio Capital Partners LLC Makes New $557,000 Investment in Gilead Sciences, Inc. $GILD

Proficio Capital Partners LLC purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 4,405 shares of the biopharmaceutical company’s stock, valued at approximately $557,000.

A number of other hedge funds have also modified their holdings of GILD. BlackRock Inc. acquired a new stake in Gilead Sciences during the 2nd quarter valued at $15,393,785,000. Norges Bank acquired a new position in shares of Gilead Sciences in the fourth quarter valued at approximately $2,617,152,000. Legal & General Group Plc purchased a new position in shares of Gilead Sciences during the second quarter valued at approximately $1,316,606,000. Deutsche Bank AG purchased a new position in shares of Gilead Sciences during the second quarter valued at approximately $918,387,000. Finally, Boston Partners acquired a new stake in Gilead Sciences during the fourth quarter worth approximately $517,808,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Price Performance

GILD opened at $149.61 on Thursday. The firm has a market cap of $185.51 billion, a price-to-earnings ratio of -56.03 and a beta of 0.33. Gilead Sciences, Inc. has a fifty-two week low of $108.46 and a fifty-two week high of $157.29. The company’s 50-day moving average price is $135.66 and its 200 day moving average price is $136.45. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($7.25) by $0.50. The company had revenue of $7.80 billion for the quarter, compared to analysts’ expectations of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The firm’s quarterly revenue was up 10.6% compared to the same quarter last year. During the same period last year, the business posted $2.01 earnings per share. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post -0.47 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.82 per share. The ex-dividend date is Tuesday, September 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.2%. Gilead Sciences’s dividend payout ratio (DPR) is -122.85%.

Analyst Ratings Changes

Several research analysts recently commented on GILD shares. Leerink Partners lowered shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and cut their price target for the company from $146.00 to $127.00 in a report on Tuesday, July 21st. Maxim Group upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price target for the company in a research note on Wednesday, May 20th. Needham & Company LLC restated a “buy” rating and issued a $170.00 target price on shares of Gilead Sciences in a research note on Wednesday, August 5th. Weiss Ratings cut shares of Gilead Sciences from a “buy (b-)” rating to a “hold (c-)” rating in a research report on Tuesday, August 11th. Finally, Barclays decreased their price target on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $158.04.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $138.36, for a total value of $415,080.00. Following the sale, the chief financial officer directly owned 165,646 shares in the company, valued at approximately $22,918,780.56. The trade was a 1.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $137.64, for a total transaction of $3,853,920.00. Following the sale, the insider owned 118,234 shares of the company’s stock, valued at $16,273,727.76. The trade was a 19.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 105,000 shares of company stock worth $14,495,820. 0.30% of the stock is owned by corporate insiders.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Zacks upgraded Gilead to “Strong Buy.” The upgrade reflects improving expectations for the company’s earnings outlook and could encourage additional buying interest. Gilead Upgraded to Strong Buy
• Positive Sentiment: Zacks raised its 2027 EPS forecasts across every quarter and for the full year. Estimates increased to $2.09 for Q1, $2.24 for Q2, $2.43 for Q3, $2.60 for Q4 and $9.36 for full-year 2027, signaling modestly stronger anticipated profitability. Zacks Gilead Upgrade and Forecasts
• Positive Sentiment: FDA approval of Bixlenvo expands Gilead’s HIV portfolio. The single-tablet treatment is aimed at underserved patients and could provide a new source of growth, though commercial adoption will determine its financial impact. Bixlenvo HIV Growth Opportunity
• Neutral Sentiment: CEO Daniel O’Day sold 15,000 shares worth approximately $2.23 million. The transaction reduced his holdings by 2.53%, but it was executed under a pre-arranged Rule 10b5-1 plan, making it a weaker bearish signal than an unexpected discretionary sale. SEC Insider Trading Filing

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.